
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.**

Date of Report: January 21, 2008
(Date of earliest event reported)

Oragenics, Inc

(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

000-32188
(Commission File Number)

59-3410522
(IRS Employer
Identification Number)

13700 Progress Blvd
(Address of principal executive offices)

32615
(Zip Code)

386-418-4018
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Election of Directors; Appointment of Principal Officers

On January 21, 2008, the Company announced the appointment of two new Directors, Mr. Derek Hennecke and Mr. Stanley Stein. On a previous filed 8-K, Mr. Hennecke's appointment to serve on the Board of Directors as an independent director was announced bringing the Board to five directors of which three members are independent directors. In connection with his appointment, Mr. Hennecke was awarded 65,000 stock options at an exercise price of \$0.41 which will vest immediately. Mr. Hennecke will be expected to serve on the audit committee.

Concurrently with the above, the Company also announced the appointment of Stanley B. Stein, as a director to the Board of Directors. Stan Stein is a principal at Scarsdale Equities in New York, NY. His twenty-five years of investment banking experience will greatly assist Orogenics in networking with biopharma companies and investment groups. Previously, he was Head of North American Corp. Finance for Dresdner Bank. He founded SRS Capital LLC, a small banking boutique that specializes in healthcare. He was also a principle in creating Fresenius Medical Care, the largest renal care business in the world. Stan received his BA and JD from Columbia University.

With Stan Stein's acceptance to serve as a Board member, this will bring the Board to six directors of which three members are independent directors. In connection with his appointment, Mr. Stein was awarded 65,000 stock options at an exercise price of \$0.49 which will vest immediately.

A copy of the January 21, 2008 press release announcing the appointment of two new Board Members is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Information and Exhibits

(c) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release of Orogenics, Inc. dated January 21, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 23, 2008

ORAGENICS, INC

By: /s/ Ronald P. Evens

Ronald P Evens,
CEO & President

Oragenics announces the Appointment of Two New Board Members

Alachua, FL (January 21, 2008) – Oragenics, Inc. (AMEX:ONI), a biotechnology development company, announced today further expansion of the Board of Directors with two talented and experienced Board members, Derek Hennecke and Stanley B. Stein.

New Board Member: Derek Hennecke MBA is an expert in drug development. He is a founder and CEO of Xcelience, a formulation and clinical manufacturing contract research company in Tampa, Florida. His management experiences over 25 years in the international biotechnology industry include; MDS Pharma Sciences, as Vice-president and General Manager for biopharmaceuticals, formulations, manufacturing, and pharmaceuticals; DSM (contract manufacturing company) in active pharmaceutical ingredients, new business development (NBD) and manufacturing; and Biochemical Research Division of Boehringer Mannheim in NBD. His work included Europe, Egypt, Mexico, Canada, and USA. He earned a BSc, University of Alberta (Canada), and MBA, Erasmus University (Rotterdam, Netherlands).

Stanley B. Stein, J.D. is a registered securities principal at Scarsdale Equities in New York, NY, focusing in healthcare and biotechnology. His investment banking experience covers 25 years and many complex transactions. Previously, he was Head of the North American Corporate Finance for Dresdner Bank. Stan also was a Managing Director at Drexel Burnham Lambert. He founded a small banking boutique, SRS Capital LLC, specializing in healthcare. He was a principal in creating Fresenius Medical Care, the largest renal care business in the world. Stan brings to Oragenics a network of biopharma companies, investment groups, and other business relationships. Stan received his B.A and J.D. from Columbia University in New York. Stan will be focusing on new business development and new investments for Oragenics.

Dr. Ron Evens (CEO) and David Gury (Chairman) stated, “Oragenics continues to execute and further our science and business goals by bringing in talented new Board members with highly valued and applicable expertises, especially adding skills in new business development and financing.” Dr. Ron Evens further stated that, “Oragenics continues its evolution from an oral care company to an infectious disease company with multiple platforms and product opportunities”.

About Oragenics: Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and weight loss. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid state synthesis of bioactive peptides including small molecule antibiotics.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,”

“estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact:

Oragenics, Inc.
Ronald P. Evens, 386-418-4018 X222
www.oragenics.com